Ritterband David C, Shapiro Daniel, Trubnik Valeriya, Marmor Michael, Meskin Seth, Seedor John, Liebmann Jeffrey M, Tello Celso, Koplin Richard, Harizman Noga, Shabto Uri, Ritch Robert
Department of Ophthalmology, New York Eye & Ear Infirmary, New York, NY 10003, USA.
Cornea. 2007 Oct;26(9):1060-6. doi: 10.1097/ICO.0b013e3181342835.
To study the outcome of penetrating keratoplasty (PK) in eyes undergoing simultaneous insertion or repositioning of a glaucoma drainage device (GDD) through the pars plana.
The medical records of all patients who underwent PK and primary placement or repositioning of a GDD through the pars plana from April 1, 1997, through December 1, 2005, were reviewed. Intraocular pressure (IOP) control was defined as maintenance of IOP > or = 5 and < or = 21 mm Hg (without loss of light perception vision or needing further glaucoma surgery). Kaplan-Meier life table survival analysis was used to estimate the success of graft survival (clarity) and glaucoma control.
Eighty-three eyes of 80 patients (34 men and 46 women) were identified. Mean follow-up was 16 months (range, 6-96 months). PK and pars plana vitrectomy were performed with primary pars plana GDD insertion (57 eyes) or tube repositioning from the anterior chamber to pars plana (26 eyes). Grafts remained clear in 93% of eyes (76/83) at 6 months, 87% (56/66) at 1 year, and 59% (19/32) at 2 years. IOP was controlled in 87% (72/83) of eyes at 6 months, 95% (57/63) at 1 year, and 83% (20/24) at 2 years.
PK with simultaneous pars plana GDD repositioning or placement showed comparable short- and long-term IOP control to that of previous studies with limbal-based GDD. The rate of corneal graft failure and the rate of immunologic rejection were comparable to or lower than those reported in other series with primary limbal-based GDD.
研究穿透性角膜移植术(PK)联合经睫状体扁平部植入或重新放置青光眼引流装置(GDD)的手术效果。
回顾1997年4月1日至2005年12月1日期间所有接受PK手术并经睫状体扁平部初次植入或重新放置GDD的患者的病历。眼压(IOP)控制定义为眼压维持在≥5且≤21 mmHg(无光感视力丧失或无需进一步青光眼手术)。采用Kaplan-Meier生存分析表评估植片存活(透明度)和青光眼控制的成功率。
共纳入80例患者的83只眼(男性34例,女性46例)。平均随访时间为16个月(范围6 - 96个月)。PK联合睫状体扁平部玻璃体切除术同时进行睫状体扁平部GDD初次植入(57只眼)或将引流管从前房重新放置到睫状体扁平部(26只眼)。术后6个月时,93%(76/83)的植片保持透明,1年时为87%(56/66),2年时为59%(19/32)。术后6个月时,87%(72/83)的眼眼压得到控制,1年时为95%(57/63),2年时为83%(20/24)。
PK联合睫状体扁平部GDD重新放置或植入术在短期和长期眼压控制方面与以往基于角膜缘的GDD研究结果相当。角膜移植失败率和免疫排斥率与其他系列基于角膜缘的初次GDD研究报道相当或更低。